Biologics Market Synopsis

Biologics Market Size is Valued at USD 561.75 Billion in 2024 and is Projected to Reach USD 1230.70 Billion by 2032, Growing at a CAGR of 10.3% From 2024-2032.

The pharmaceutical market is comprised of biologics which are medicines and treatments that are produced from biological organisms or using related processes. Some of these products are highly sophisticated and also big structures made of big molecules such as antibodies, vaccines, gene therapies, and cell therapies among others. The primary application of biologics is in the treatment of diseases that range from cancer to autoimmune disorders, and genetic disorders. The prevalence can be described through high levels of R&D costs, regulatory pressures, and specific production technologies. It is a very robust market that is expanding because of the growing need in the healthcare industry for a more individual approach to the treatment of patients and the constant progress in the field of biotechnology.

• The global biologics market has been influenced by some driving forces, which include the following. Some of the main factors include the rise of various chronic diseases which include cancer, autoimmune diseases, and infectious diseases. The conditions are treatable by biologic therapy which is very specific and thus makes use to healthcare providers and patients.
• The other key trend impacting the biologics market is the increasing geriatric population in the developed countries of the world. Undoubtedly, the aging population has put a premium on biologics as they are more effective in their treatment of chronic and degenerative diseases than traditional chemical compounds. Second, the knowledge of biotechnology and genetic engineering has enhanced the production of biologic drugs and created more complex biological drugs which have triggered market growth. Some other factors that have also proved to boost market growth include the rising acceptance and integration of biologics as a viable treatment choice by regulatory bodies and healthcare providers.

Biologics Market Trend Analysis

Biosimilars, Disrupting the Biologics Landscape

• The market for biologics has also remained significantly dynamic and is being buoyed by effects like higher incidences of chronic ailments, evolving technology in the biomedical industry, and growing trends in the consumerization of drugs. Since most biologics are obtained from living organisms, they tend to provide targeted and effective treatments for diseases such as cancer, auto-immune, and genetic diseases.
• Another significant movement related to the business is the tendency towards the increase in biosimilars’ usage. These are products that are highly similar to given bioequivalent products but at a comparatively lower price than branded bioequivalent products. Biosimilar growth will depend also on the expiration of exclusivity rights of several biological drugs leading to an increase in competition and a decrease in the cost of the treatments.
• Another, when one considers trends, is the ongoing rise of biologics in the treatment of cancer. Biologic monoclonal antibodies are yet to be widely used but they are already ensuring selective treatment of cancer with minimal side effects like chemotherapy. Consequently, as the range of biologic targets and therapeutic strategies revealed by the investigation expands, the oncology sector in the biologics market is projected to experience significant growth.

The Rise of Biologics, Exploring Opportunities in a Dynamic Market

• Biologics is another core area of growth that has seen tremendous growth worldwide, providing good opportunities to both established pharma players and new players. The biologics or biotherapeutic agents which are large molecules synthesized from biological sources are being given importance over small molecule drugs due to their high target selectivity and better therapeutic efficacy in managing different diseases.
• The development of biologic drugs remains fueled by the ever-rising tendencies of chronic illnesses including; different cancers, autoimmune diseases, and diabetes. Biologics in the form of drug treatments for these diseases are much more effective compared to the side effects that are associated with conventional medication. This has surely translated to increased consumption of biologics and heightened activity in the research and development sector particularly in this niche.
• Also, the reach and importance of the biologics market are due to the fact of innovations and improvements in Biotechnology and Genetic engineering that have facilitated the manufacture of sophisticated and efficient biological drugs. The market is also experiencing a shift towards personalized drugs, which are developed using biological processes and targeting specific patient’s genetic profiles of the patient further spurring development in the field.
• Altogether, the market of biologics is expected to hold a significant potential containing several opportunities for development for pharmaceutical companies interested in diversifying their production offering a growing number of innovative products for the treatment of various diseases in different therapeutic classes. Yet, they face issues like regional regulations which make it challenging to farm, and they need to continually innovate through research to be relevant in the fast-growing market.

Biologics Market Segment Analysis:

Biologics Market Segmented based on Product Type, Manufacturing Process, application, and end-users.

By Product Type, Vaccines segment is expected to dominate the market during the forecast period

• The biologics market is classified depending on the kind of products as follows; Monoclonal antibodies, Vaccines, Recombs or recombinant hormones/proteins, Cell therapy, Gene therapy, and all the other biologics. continuing with the prodigious advanced drugs, the segment of monoclonal antibodies for targeted therapy of diseases such as cancer or autoimmune diseases enrolled one of the highest shares. Anticipative measures like vaccines are important in eradicating certain Diseases and are also of great importance in public health. Biological drugs in use include recombinant hormones/proteins and other therapies, for example in cell therapy, and in gene therapy. By including all of the other entries under this broad category of “other biologics”, it makes up part of the BOSS that hails the rich variety of biologic therapeutics. Altogether, these product types contribute significantly to market growth and development and hold the potential to address numerous diseases and medical conditions impacting the lives of patients and consumers.

By Application, Oncology segment held the largest share in 2024

• Biologics is utilized in many diseases and can be classified across multiple therapeutic areas such as Oncology, Infectious Diseases, Immunology, Autoimmune diseases, Genetic diseases, and Other Biologic Products. In oncology, drugs like monoclonal antibodies are utilized for targeted treatments of cancer. For instance, biologics can also be used to manage infectious diseases with vaccines seen as one of the major interventions in the management of the diseases. Immunology employs biological products in treating diseases such as rheumatoid arthritis and psoriasis based on immune system regulation. In the case of autoimmune diseases, the biologics are aimed at particular immunologic reactions. Like gene therapy, biologics help offer potential cures or treatments for inherited diseases or other genetic complications. Other uses of biologics remain to be availed also, proving how biologic drugs are useful in many different requirements in the medical field.

Biologics Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• The North American biologics market has become a significant component of the global pharmaceutical market and is a region of vitally important companies operating in the sector of biopharmaceuticals, as well as research organizations and an encouraging regulatory environment. The growth of the regional market is attributable to factors including a rising incidence of chronic diseases, a growing focus on … tailored healthcare services, and developments in biotechnology.
• Biologic drugs in the North American market are driven majorly by the United States because of the discovery of new biologic drugs and its higher revenue. The presence of a robust biotechnology industry and positive government regulations towards Biopharmaceuticals are established drivers behind the market development. Canada is another key player in the biologics market within the region, recognized for the increasing levels of innovation and market growth in response to the growing amount of biotechnology companies and research institutes. Altogether, it can be stated that the current and future growth of the North American biologics market is subject to sustainable growth due to the increased investments in the research and development of various functioning therapeutic pipelines, biopharmaceutical and a growing trend towards biologics in numerous functions and uses.

Active Key Players in the Biologics Market

• Samsung Biologics (South Korea)
• Amgen Inc. (United States)
• Novo Nordisk A/S (Denmark)
• AbbVie Inc. (United States)
• Sanofi (France)
• Johnson & Johnson Services, Inc. (United States)
• Celltrion Healthcare Co., Ltd. (South Korea)
• Bristol-Myers Squibb Company (United States)
• Eli Lilly and Company (United States)
• F. Hoffmann La-Roche Ltd. (Switzerland), and Other Active Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Biologics Market by Product Type
 4.1 Biologics Market Snapshot and Growth Engine
 4.2 Biologics Market Overview
 4.3 Monoclonal Antibodies
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Monoclonal Antibodies: Geographic Segmentation Analysis
 4.4 Vaccines
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Vaccines: Geographic Segmentation Analysis
 4.5 Recombinant Hormones/Proteins
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Recombinant Hormones/Proteins: Geographic Segmentation Analysis
 4.6 Cell Therapy
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Cell Therapy: Geographic Segmentation Analysis
 4.7 Gene Therapy
  4.7.1 Introduction and Market Overview
  4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.7.3 Key Market Trends, Growth Factors and Opportunities
  4.7.4 Gene Therapy: Geographic Segmentation Analysis
 4.8 Other Biologics
  4.8.1 Introduction and Market Overview
  4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.8.3 Key Market Trends, Growth Factors and Opportunities
  4.8.4 Other Biologics: Geographic Segmentation Analysis

Chapter 5: Biologics Market by Manufacturing Process
 5.1 Biologics Market Snapshot and Growth Engine
 5.2 Biologics Market Overview
 5.3 Upstream Processing
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Upstream Processing: Geographic Segmentation Analysis
 5.4 Downstream Processing
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Downstream Processing: Geographic Segmentation Analysis

Chapter 6: Biologics Market by Application
 6.1 Biologics Market Snapshot and Growth Engine
 6.2 Biologics Market Overview
 6.3 Oncology
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Oncology: Geographic Segmentation Analysis
 6.4 Infectious Diseases
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Infectious Diseases: Geographic Segmentation Analysis
 6.5 Immunology
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Immunology: Geographic Segmentation Analysis
 6.6 Autoimmune Diseases
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Autoimmune Diseases: Geographic Segmentation Analysis
 6.7 Genetic Disorders
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Genetic Disorders: Geographic Segmentation Analysis
 6.8 Other Applications
  6.8.1 Introduction and Market Overview
  6.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.8.3 Key Market Trends, Growth Factors and Opportunities
  6.8.4 Other Applications: Geographic Segmentation Analysis

Chapter 7: Biologics Market by End-User
 7.1 Biologics Market Snapshot and Growth Engine
 7.2 Biologics Market Overview
 7.3 Hospitals
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospitals: Geographic Segmentation Analysis
 7.4 Clinics
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Clinics: Geographic Segmentation Analysis
 7.5 Research Institutes
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Research Institutes: Geographic Segmentation Analysis
 7.6 Others
  7.6.1 Introduction and Market Overview
  7.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.6.3 Key Market Trends, Growth Factors and Opportunities
  7.6.4 Others : Geographic Segmentation Analysis

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Benchmarking
  8.1.2 Biologics Market Share by Manufacturer (2023)
  8.1.3 Industry BCG Matrix
  8.1.4 Heat Map Analysis
  8.1.5 Mergers and Acquisitions
  
 8.2 SAMSUNG BIOLOGICS
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Role of the Company in the Market
  8.2.5 Sustainability and Social Responsibility
  8.2.6 Operating Business Segments
  8.2.7 Product Portfolio
  8.2.8 Business Performance
  8.2.9 Key Strategic Moves and Recent Developments
  8.2.10 SWOT Analysis
 8.3 AMGEN INC
 8.4 NOVO NORDISK A/S
 8.5 ABBVIE INC
 8.6 SANOFI
 8.7 JOHNSON & JOHNSON SERVICES
 8.8 INC
 8.9 CELLTRION HEALTHCARE CO
 8.10 LTD
 8.11 BRISTOL-MYERS SQUIBB COMPANY
 8.12 ELI LILLY AND COMPANY (UNITED STATES)
 8.13 FHOFFMANN LA-ROCHE LTD
 8.14 OTHER ACTIVE PLAYERS

Chapter 9: Global Biologics Market By Region
 9.1 Overview
 9.2. North America Biologics Market
  9.2.1 Key Market Trends, Growth Factors and Opportunities
  9.2.2 Top Key Companies
  9.2.3 Historic and Forecasted Market Size by Segments
  9.2.4 Historic and Forecasted Market Size By Product Type
   9.2.4.1 Monoclonal Antibodies
   9.2.4.2 Vaccines
   9.2.4.3 Recombinant Hormones/Proteins
   9.2.4.4 Cell Therapy
   9.2.4.5 Gene Therapy
   9.2.4.6 Other Biologics
  9.2.5 Historic and Forecasted Market Size By Manufacturing Process
   9.2.5.1 Upstream Processing
   9.2.5.2 Downstream Processing
  9.2.6 Historic and Forecasted Market Size By Application
   9.2.6.1 Oncology
   9.2.6.2 Infectious Diseases
   9.2.6.3 Immunology
   9.2.6.4 Autoimmune Diseases
   9.2.6.5 Genetic Disorders
   9.2.6.6 Other Applications
  9.2.7 Historic and Forecasted Market Size By End-User
   9.2.7.1 Hospitals
   9.2.7.2 Clinics
   9.2.7.3 Research Institutes
   9.2.7.4 Others
  9.2.8 Historic and Forecast Market Size by Country
   9.2.8.1 US
   9.2.8.2 Canada
   9.2.8.3 Mexico
 9.3. Eastern Europe Biologics Market
  9.3.1 Key Market Trends, Growth Factors and Opportunities
  9.3.2 Top Key Companies
  9.3.3 Historic and Forecasted Market Size by Segments
  9.3.4 Historic and Forecasted Market Size By Product Type
   9.3.4.1 Monoclonal Antibodies
   9.3.4.2 Vaccines
   9.3.4.3 Recombinant Hormones/Proteins
   9.3.4.4 Cell Therapy
   9.3.4.5 Gene Therapy
   9.3.4.6 Other Biologics
  9.3.5 Historic and Forecasted Market Size By Manufacturing Process
   9.3.5.1 Upstream Processing
   9.3.5.2 Downstream Processing
  9.3.6 Historic and Forecasted Market Size By Application
   9.3.6.1 Oncology
   9.3.6.2 Infectious Diseases
   9.3.6.3 Immunology
   9.3.6.4 Autoimmune Diseases
   9.3.6.5 Genetic Disorders
   9.3.6.6 Other Applications
  9.3.7 Historic and Forecasted Market Size By End-User
   9.3.7.1 Hospitals
   9.3.7.2 Clinics
   9.3.7.3 Research Institutes
   9.3.7.4 Others
  9.3.8 Historic and Forecast Market Size by Country
   9.3.8.1 Bulgaria
   9.3.8.2 The Czech Republic
   9.3.8.3 Hungary
   9.3.8.4 Poland
   9.3.8.5 Romania
   9.3.8.6 Rest of Eastern Europe
 9.4. Western Europe Biologics Market
  9.4.1 Key Market Trends, Growth Factors and Opportunities
  9.4.2 Top Key Companies
  9.4.3 Historic and Forecasted Market Size by Segments
  9.4.4 Historic and Forecasted Market Size By Product Type
   9.4.4.1 Monoclonal Antibodies
   9.4.4.2 Vaccines
   9.4.4.3 Recombinant Hormones/Proteins
   9.4.4.4 Cell Therapy
   9.4.4.5 Gene Therapy
   9.4.4.6 Other Biologics
  9.4.5 Historic and Forecasted Market Size By Manufacturing Process
   9.4.5.1 Upstream Processing
   9.4.5.2 Downstream Processing
  9.4.6 Historic and Forecasted Market Size By Application
   9.4.6.1 Oncology
   9.4.6.2 Infectious Diseases
   9.4.6.3 Immunology
   9.4.6.4 Autoimmune Diseases
   9.4.6.5 Genetic Disorders
   9.4.6.6 Other Applications
  9.4.7 Historic and Forecasted Market Size By End-User
   9.4.7.1 Hospitals
   9.4.7.2 Clinics
   9.4.7.3 Research Institutes
   9.4.7.4 Others
  9.4.8 Historic and Forecast Market Size by Country
   9.4.8.1 Germany
   9.4.8.2 UK
   9.4.8.3 France
   9.4.8.4 Netherlands
   9.4.8.5 Italy
   9.4.8.6 Russia
   9.4.8.7 Spain
   9.4.8.8 Rest of Western Europe
 9.5. Asia Pacific Biologics Market
  9.5.1 Key Market Trends, Growth Factors and Opportunities
  9.5.2 Top Key Companies
  9.5.3 Historic and Forecasted Market Size by Segments
  9.5.4 Historic and Forecasted Market Size By Product Type
   9.5.4.1 Monoclonal Antibodies
   9.5.4.2 Vaccines
   9.5.4.3 Recombinant Hormones/Proteins
   9.5.4.4 Cell Therapy
   9.5.4.5 Gene Therapy
   9.5.4.6 Other Biologics
  9.5.5 Historic and Forecasted Market Size By Manufacturing Process
   9.5.5.1 Upstream Processing
   9.5.5.2 Downstream Processing
  9.5.6 Historic and Forecasted Market Size By Application
   9.5.6.1 Oncology
   9.5.6.2 Infectious Diseases
   9.5.6.3 Immunology
   9.5.6.4 Autoimmune Diseases
   9.5.6.5 Genetic Disorders
   9.5.6.6 Other Applications
  9.5.7 Historic and Forecasted Market Size By End-User
   9.5.7.1 Hospitals
   9.5.7.2 Clinics
   9.5.7.3 Research Institutes
   9.5.7.4 Others
  9.5.8 Historic and Forecast Market Size by Country
   9.5.8.1 China
   9.5.8.2 India
   9.5.8.3 Japan
   9.5.8.4 South Korea
   9.5.8.5 Malaysia
   9.5.8.6 Thailand
   9.5.8.7 Vietnam
   9.5.8.8 The Philippines
   9.5.8.9 Australia
   9.5.8.10 New Zealand
   9.5.8.11 Rest of APAC
 9.6. Middle East & Africa Biologics Market
  9.6.1 Key Market Trends, Growth Factors and Opportunities
  9.6.2 Top Key Companies
  9.6.3 Historic and Forecasted Market Size by Segments
  9.6.4 Historic and Forecasted Market Size By Product Type
   9.6.4.1 Monoclonal Antibodies
   9.6.4.2 Vaccines
   9.6.4.3 Recombinant Hormones/Proteins
   9.6.4.4 Cell Therapy
   9.6.4.5 Gene Therapy
   9.6.4.6 Other Biologics
  9.6.5 Historic and Forecasted Market Size By Manufacturing Process
   9.6.5.1 Upstream Processing
   9.6.5.2 Downstream Processing
  9.6.6 Historic and Forecasted Market Size By Application
   9.6.6.1 Oncology
   9.6.6.2 Infectious Diseases
   9.6.6.3 Immunology
   9.6.6.4 Autoimmune Diseases
   9.6.6.5 Genetic Disorders
   9.6.6.6 Other Applications
  9.6.7 Historic and Forecasted Market Size By End-User
   9.6.7.1 Hospitals
   9.6.7.2 Clinics
   9.6.7.3 Research Institutes
   9.6.7.4 Others
  9.6.8 Historic and Forecast Market Size by Country
   9.6.8.1 Turkey
   9.6.8.2 Bahrain
   9.6.8.3 Kuwait
   9.6.8.4 Saudi Arabia
   9.6.8.5 Qatar
   9.6.8.6 UAE
   9.6.8.7 Israel
   9.6.8.8 South Africa
 9.7. South America Biologics Market
  9.7.1 Key Market Trends, Growth Factors and Opportunities
  9.7.2 Top Key Companies
  9.7.3 Historic and Forecasted Market Size by Segments
  9.7.4 Historic and Forecasted Market Size By Product Type
   9.7.4.1 Monoclonal Antibodies
   9.7.4.2 Vaccines
   9.7.4.3 Recombinant Hormones/Proteins
   9.7.4.4 Cell Therapy
   9.7.4.5 Gene Therapy
   9.7.4.6 Other Biologics
  9.7.5 Historic and Forecasted Market Size By Manufacturing Process
   9.7.5.1 Upstream Processing
   9.7.5.2 Downstream Processing
  9.7.6 Historic and Forecasted Market Size By Application
   9.7.6.1 Oncology
   9.7.6.2 Infectious Diseases
   9.7.6.3 Immunology
   9.7.6.4 Autoimmune Diseases
   9.7.6.5 Genetic Disorders
   9.7.6.6 Other Applications
  9.7.7 Historic and Forecasted Market Size By End-User
   9.7.7.1 Hospitals
   9.7.7.2 Clinics
   9.7.7.3 Research Institutes
   9.7.7.4 Others
  9.7.8 Historic and Forecast Market Size by Country
   9.7.8.1 Brazil
   9.7.8.2 Argentina
   9.7.8.3 Rest of SA

Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies

Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research